BRCA1 and breast carcinoma: Results were in agreement with Rebbeck et al., showing that HRT use following RRBSO was not associated with an increase in risk of breast cancer in BRCA1 and BRCA2 mutation carriers (HR 0.52 [95% CI 0.30, 0.92] and HR 0.24 [95% CI 0.05, 1.03], respectively).